1例肾移植患者乙肝病毒激活的临床治疗  

Clinical Treatment of One Case Hepatitis B Virus Activation of Renal Transplant Patients

作　　者：张巍 黄政宇 张景昆 ZHANG Wei;HUANG Zheng-yu;ZHANG Jing-kun(Department of Infection,Pingquan City Hospital,Chengde,Hebei,06750)

机构地区：[1]平泉市医院感染科,河北承德067500

出　　处：《智慧健康》2018年第21期29-30,共2页Smart Healthcare

基　　金：中西医结治疗顽固性腹水;编号:201021098

摘　　要：携带乙肝病毒的非肝脏移植患者其潜在的乙肝病毒再激活风险已经受到多个肾移植中心、骨髓移植中心、健康生殖中心等的广泛重视,我院发生1例肾移植患者携带乙肝病毒,移植后服用肾上腺皮质激素、免疫抑制剂治疗后出现体内病毒大量复制,及时选用恩替卡韦抗病毒治疗,患者原发耐药,给治疗造成一定困惑。经DNA序列检测及时调整用药,治疗获得成功。结合文献和共识,提高非肝脏移植前患者筛查,预防病毒激活。为移植中心和肝病科医生提供一定的参考。Reactivation risks of hepatitis B virus（HBV） of non liver transplant patients with HBV has been paid extensive attention by multiple renal transplantation centers, bone marrow transplantation centers and healthy reproductive centers. One case renal transplantation patient with HBV in our hospital had massive virus replication in vivo after treatment of adrenocortical hormone and immunodepressants after transplantation, which was treated with entecavir antivirus in time. Primary drug resistance of patient brought some certain perplexity for treatment. Treatment was successful based on DNA sequence test and timely medication adjustment. Combined with literature and consensus, the article discusses screening improvement of non liver transplant patients to prevent viral activation, and provide some certain reference for transplant center and hepatology doctors.

关 键 词：肾移植 携带乙肝病毒 原发耐药 

分 类 号：R512.62[医药卫生—内科学] R699.2[医药卫生—临床医学]